Immunitas Therapeutics Completes $58 Million Series B Financing to Advance
Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform
for Immuno-Oncology and Other Diseases
Series B financing led by Agent Capital
Funding to advance novel NK and T cell modulator IMT-009 for the treatment of solid tumor andhematological cancers with an anticipated IND filing in 1H 2022
Expands leadership team with appointment of Chief Business Officer Amanda Wagner, appoints Geeta
Vemuri, Agent Capital, and Brian Halak, on behalf of MEC, to Immunitas Board of Directors

Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based
therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital withparticipation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture
Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and
The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). Existing investors Alexandria
Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor
Longwood Fund also joined the round. As part of the financing, Geeta Vemuri, PhD, MBA, Managing Partner andFounder of Agent Capital, and Brian Halak, PhD, on behalf of MEC will join the Immunitas Board of Directors.
“Immunitas has made tremendous strides in the past year. This Series B financing is a key inflection point for thecompany and will enable us to drive IMT-009 rapidly into the clinic, while continuing to build and validate our pipelineof novel oncology programs,” said Jeffrey Goldberg, Chief Executive Officer of Immunitas Therapeutics. “Our single
cell technology platform allows our team to incorporate insights from human biology throughout the discovery anddevelopment process, enabling us to rapidly move towards serving patients in need.”
The Series B funding will be used to advance Immunitas’ lead program, IMT-009, a CD161 inhibitor, into the clinic totreat both solid tumors and hematological malignancies. Both blockade and knockout of CD161 in preclinical systems
have shown enhanced tumor-killing, increases in critical cytokines, and increased survival. The company expects tofile its first Investigational New Drug application (IND) in 1H 2022 for IMT-009. This financing builds on the $39 million
Series A financing secured in 2019. Immunitas Therapeutics was founded by Kai Wucherpfennig, MD, PhD, DanaFarber Cancer Institute, K. Dane Wittrup, PhD, the Massachusetts Institute of Technology (MIT), Mario Suvà, MD,PhD, Massachusetts General Hospital (MGH), and Aviv Regev, PhD, MIT.
1

“Immunitas is focused on creating impactful therapies that modulate oncology targets, driven by a cross-functional
platform that combines single cell analysis computation and molecular and cellular biology to rapidly identify andvalidate new targets,” said Geeta Vemuri of Agent Capital. “This approach is well suited to provide powerfultranslational insights into biomarker and indication selection with long-term potential beyond IO.”
In addition, Amanda Wagner, MBA, has been appointed Chief Business Officer in recognition of her significant
contributions to the company’s business and corporate development. Ms. Wagner was one of the earliest employeesof Immunitas, joining the company in October 2019 as Vice President of Strategy. Ms. Wagner has more than 15years of experience in drug discovery, drug development, and medical technology, and has led teams to identify,research, and develop novel immune-modulating therapies. At Immunitas, Ms. Wagner has led the structuring andnegotiation of multiple strategic collaborations and driven the progression of the lead program and pipeline. Prior tojoining Immunitas, she was Vice President of Corporate Development at Q32 Bio, where she contributed to thecompany’s $46 million Series A. Previously, Ms. Wagner was at Concert Pharmaceuticals, where she managed a$250 million asset sale, directly contributed to the Initial Public Offering, and identified and led the development of apreclinical therapeutic for autoimmune disease, now in Phase 3. Prior to Concert, Ms. Wagner was an early memberof the team at UpToDate, Inc. Ms. Wagner also sits on the Board of Directors of the National Alopecia AreataFoundation.

About Immunitas Therapeutics
Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple
programs to the clinic. Immunitas’ programs are derived from their platform, a cross-functional, highly integrated,single cell genomics approach that enables rapid target identification and validation in parallel with antibody
discovery and engineering. IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed forthe treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target
NK and T cell modulator. The company was founded by Longwood Fund with leading scientists from Dana-Farber,
MGH, the Broad, and MIT. Since being founded in 2019, Immunitas has raised a total of $97 million in venture
funding from a strong syndicate of investors including Longwood Fund, Alexandria, Evotec, Leaps by Bayer, M
Ventures, and Novartis Venture Fund (NVF). To learn more, visit www.immunitastx.com

2About Agent Capital
Agent Capital is an international life sciences investment firm that supports disruptive healthcare companies focusing
on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns withscientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages
their industry expertise and successful track record to source premier deals, accelerate value, and drive successfulexits. Their first fund invested in 15 portfolio companies, majority of them have executed collaborations with major
pharmaceutical companies and successfully raised additional capital in the private or public markets. Agent Capitalhas offices in Boston, Massachusetts.

Media Contact:
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

3